TY - JOUR
T1 - Up-regulation of nicotinic acetylcholine receptors by central-type acetylcholinesterase inhibitors in rat cortical neurons
AU - Kume, Toshiaki
AU - Sugimoto, Mitsuhiro
AU - Takada, Yuki
AU - Yamaguchi, Toshiaki
AU - Yonezawa, Atsushi
AU - Katsuki, Hiroshi
AU - Sugimoto, Hachiro
AU - Akaike, Akinori
N1 - Funding Information:
This work was supported in part by a grant-in-aid for Scientific Research and a grant-in-aid on priority areas from the Ministry of Education, Science, Sports and Culture (Japan). This study was also supported in part by a grant from the Smoking Research Foundation (Japan).
PY - 2005/12/19
Y1 - 2005/12/19
N2 - We previously reported that donepezil, a central-type acetylcholinesterase inhibitor, showed neuroprotective action via α4-and α7-nicotinic acetylcholine receptors against glutamate neurotoxicity in rat cortical culture. The present study was performed to investigate whether the neuroprotective action of acetylcholinesterase inhibitors is accompanied by the alteration of expression and function of nicotinic receptors. Four days treatment with acetylcholinesterase inhibitors (10 μM) enhanced the nicotine-induced increase of the intracellular calcium concentration. Immunoblot analysis revealed that donepezil increased both α4 and α7 subunit proteins. Donepezil and galanthamine increased the number of cells expressing α4- and α7-nicotinic receptors in immunocytochemical analysis. We examined whether up-regulation of nicotinic receptors affected the neuroprotective action of acetylcholinesterase inhibitors. Under up-regulating conditions, donepezil and galanthamine exerted neuroprotective action at lower concentrations. These results suggest that donepezil and galanthamine up-regulate nicotinic receptors in cortical neurons, and that the up-regulation of nicotinic receptors may make cortical neurons more sensitive to the neuroprotective action of donepezil and galanthamine.
AB - We previously reported that donepezil, a central-type acetylcholinesterase inhibitor, showed neuroprotective action via α4-and α7-nicotinic acetylcholine receptors against glutamate neurotoxicity in rat cortical culture. The present study was performed to investigate whether the neuroprotective action of acetylcholinesterase inhibitors is accompanied by the alteration of expression and function of nicotinic receptors. Four days treatment with acetylcholinesterase inhibitors (10 μM) enhanced the nicotine-induced increase of the intracellular calcium concentration. Immunoblot analysis revealed that donepezil increased both α4 and α7 subunit proteins. Donepezil and galanthamine increased the number of cells expressing α4- and α7-nicotinic receptors in immunocytochemical analysis. We examined whether up-regulation of nicotinic receptors affected the neuroprotective action of acetylcholinesterase inhibitors. Under up-regulating conditions, donepezil and galanthamine exerted neuroprotective action at lower concentrations. These results suggest that donepezil and galanthamine up-regulate nicotinic receptors in cortical neurons, and that the up-regulation of nicotinic receptors may make cortical neurons more sensitive to the neuroprotective action of donepezil and galanthamine.
KW - Acetylcholinesterase inhibitor
KW - Alzheimer's disease
KW - Neuroprotection
KW - Nicotinic acetylcholine receptor
KW - Up-regulation
UR - http://www.scopus.com/inward/record.url?scp=28544434902&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=28544434902&partnerID=8YFLogxK
U2 - 10.1016/j.ejphar.2005.10.028
DO - 10.1016/j.ejphar.2005.10.028
M3 - Article
C2 - 16313899
AN - SCOPUS:28544434902
SN - 0014-2999
VL - 527
SP - 77
EP - 85
JO - European Journal of Pharmacology
JF - European Journal of Pharmacology
IS - 1-3
ER -